NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)